Aptevo Therapeutics (APVO) Announces Positive Phase 2 Data for Otlertuzumab

December 16, 2016 9:09 AM
Aptevo Therapeutics Inc. (Nasdaq: APVO) announced the publication of positive data from a Phase 2 clinical trial evaluating its proprietary ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA

Next Articles